Literature DB >> 23999647

Clinical significance of the appearance of abnormal protein band in patients with multiple myeloma.

Jae-Cheol Jo1, Dok Hyun Yoon, Shin Kim, Kyoungmin Lee, Eun Hee Kang, Seongsoo Jang, Chan-Jeoung Park, Hyun-Sook Chi, Jooryung Huh, Chan-Sik Park, Cheolwon Suh.   

Abstract

Multiple myeloma (MM) is characterized by clonal expansion of malignant bone marrow cells producing a unique monoclonal immunoglobulin. The appearance of abnormal protein band (APB) in MM has been reported during follow-up. We aimed to evaluate the clinical characteristics and outcomes of patients with APB in a single center cohort. A total of 377 consecutive MM patients were treated at the Asan Medical Center between January 2002 and December 2012. We compared clinical characteristics and survival outcome between those with and without APB. Of the 377 patients, 34 (9 %) experienced APB. They comprised 18.2 % (27/148) of patients treated with autologous stem cell transplantation (ASCT) and 3.1 % (7/229) of those not receiving ASCT. APB occurred after a median of 7.9 months (range, 2.2-95.7 months) from diagnosis. Immunoglobulin isotypes at diagnosis were as follows: IgG (n = 10), IgA (n = 8), IgD (n = 5), free κ (n = 4), and free λ (n = 7). Nine patients experienced a second APB. With a median follow-up of 54.1 months, the median overall survival (OS) has not been reached in patients with APB and was 38.3 months in patients without (P < 0.001). Multivariate analysis indicated that the development of APB was a significant favorable prognostic factor for OS (hazard ratio 0.21; 95 % confidence interval 0.08-0.52). Serum β₂-microglobulin, albumin, creatinine, and ASCT were also independent prognostic factors for OS. Further investigation is required to establish the mechanisms underlying APB in MM.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23999647     DOI: 10.1007/s00277-013-1890-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  6 in total

1.  Emergence of Oligoclonal Bands in Association with the use of Chemotherapy and Hematopoietic Stem Cell Transplantation.

Authors:  Chandramallika Paul; Sarit Chakraborty; Subhosmito Chakraborty
Journal:  Indian J Clin Biochem       Date:  2021-05-19

2.  Secondary monoclonal gammopathy of undetermined significance after allogeneic stem cell transplantation in multiple myeloma.

Authors:  Marian F Schmitz; Henny G Otten; Laurens E Franssen; Suzanne van Dorp; Theo Strooisma; Henk M Lokhorst; Niels W C J van de Donk
Journal:  Haematologica       Date:  2014-09-05       Impact factor: 9.941

3.  Prospective Identification of Oligoclonal/Abnormal Band of the Same Immunoglobulin Type as the Malignant Clone by Differential Location of M-Spike and Oligoclonal Band.

Authors:  Shikhar G Vyas; Gurmukh Singh
Journal:  J Clin Med Res       Date:  2017-09-01

4.  Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma.

Authors:  Zhiyu Liang; Ping Li; Liqing Kang; Lili Zhou; Yang Xu; Shiguang Ye; Juan Du; Bing Li; Yiwen Wang; Lei Yu; Wenbin Qian; Aibin Liang
Journal:  Blood Adv       Date:  2022-01-11

5.  Oligoclonal Pattern/Abnormal Protein Bands in Post-Treatment Plasma Cell Myeloma Patients: Implications for Protein Electrophoresis and Serum Free Light Chain Assay Results.

Authors:  Gurmukh Singh
Journal:  J Clin Med Res       Date:  2017-07-01

6.  For survival, the emergence of oligoclonal bands after multiple myeloma treatment is less important than achieving complete remission.

Authors:  Luiza Soares Vieira da Silva; Edvan de Queiroz Crusoe; Lais Rocha Guimarães de Souza; Carlos Sérgio Chiattone; Vânia Tietsche de Moraes Hungria
Journal:  Rev Bras Hematol Hemoter       Date:  2017-07-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.